|
WO2021023858A1
|
|
TrkB POSITIVE ALLOSTERIC MODULATORS
|
|
WO2020127904A1
|
|
Peptides for treatment and prevention of diabetes and associated disorders
|
|
WO2020120256A1
|
|
Aptamer and use thereof
|
|
EP3811982A1
|
|
Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
|
|
EP3789427A1
|
|
Supramolecular gel supported on open-cell polymer foam
|
|
WO2019224219A1
|
|
Absolute quantification of target molecules at single-entity resolution using tandem barcoding
|
|
EP3749305A1
|
|
Compounds and compositions for the treatment of pain
|
|
EP3679952A1
|
|
Nanoemulsions encapsulating prodrugs
|
|
WO2019134994A1
|
|
Prognostic biomarkers for human papillomavirus positive cancers
|
|
KR20200098640A
|
|
Peptides for the treatment and prevention of non-alcoholic fatty liver disease and fibrosis
|
|
WO2019053269A1
|
|
Injectable hybrid alginate hydrogels and uses thereof
|
|
EP3594336A1
|
|
Treatment of down syndrome
|
|
EP3591024A1
|
|
Ultrabright luminescent lanthanide nanoparticles comprising terbium, with longer excited-state lifetime
|
|
EP3648789A1
|
|
Mtmr2-s polypeptide for use in the treatment of myopathies
|
|
EP3584249A1
|
|
Gold (i)-phosphine 1,2,3-triazole derivatives with antiobiotic properties
|
|
EP3638784A1
|
|
Methods to generate conditional knock-in models
|
|
US2020069815A1
|
|
Protein-drug conjugates and their use in the treatment of cancers
|
|
EP3546438A1
|
|
Process for the non-oxidative dehydrogenation of a hydrocarbon and uses thereof
|
|
EP3543347A1
|
|
Method of electro-cross-linking a protein with a polyphenol for the manufacture of a biosensor
|
|
EP3536806A1
|
|
Oligonucleotide-functionalized hydrophobic polymer nanoparticles
|
